Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

Hosoda, Shunichi; Suda, Goki; Sho, Takuya et al.

Liver Cancer, 2023, 12(2), 156-170

Permalink : https://hdl.handle.net/2115/89785

このアイテムのアクセス数:302件（2026-01-22 23:27 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1159/000527759     2

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
metadata only access
URI
https://hdl.handle.net/2115/89785
タイトル
Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
著者
Hosoda, Shunichi ; Suda, Goki ; Sho, Takuya ; Ogawa, Koji ; Kimura, Megumi ; Yang, Zijian ; Yoshida, Sonoe ; Kubo, Akinori ; Tokuchi, Yoshimasa ; Kitagataya, Takashi ; Maehara, Osamu ; Ohnishi, Shunsuke ; Nakamura, Akihisa ; Yamada, Ren ; Ohara, Masatsugu ; Kawagishi, Naoki ; Natsuizaka, Mitsuteru ; Nakai, Masato ; Morikawa, Kenichi ; Furuya, Ken ; Baba, Masaru ; Yamamoto, Yoshiya ; Suzuki, Kazuharu ; Izumi, Takaaki ; Meguro, Takashi ; Terashita, Katsumi ; Ito, Jun ; Miyagishima, Takuto ; Sakamoto, Naoya
著者名
Hosoda, Shunichi
e-Rad_Researcher
20447460
著者名
Suda, Goki
著者名
Sho, Takuya
著者名
Ogawa, Koji
著者名
Kimura, Megumi
著者名
Yang, Zijian
著者名
Yoshida, Sonoe
著者名
Kubo, Akinori
著者名
Tokuchi, Yoshimasa
著者名
Kitagataya, Takashi
著者名
Maehara, Osamu
著者名
Ohnishi, Shunsuke
著者名
Nakamura, Akihisa
著者名
Yamada, Ren
著者名
Ohara, Masatsugu
著者名
Kawagishi, Naoki
著者名
Natsuizaka, Mitsuteru
著者名
Nakai, Masato
著者名
Morikawa, Kenichi
著者名
Furuya, Ken
著者名
Baba, Masaru
著者名
Yamamoto, Yoshiya
著者名
Suzuki, Kazuharu
著者名
Izumi, Takaaki
著者名
Meguro, Takashi
著者名
Terashita, Katsumi
著者名
Ito, Jun
著者名
Miyagishima, Takuto
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
キーワード
Atezolizumab
Bevacizumab
Early PD
Hepatocellular carcinoma
CXCL9
Baseline
Prognosis
発行日
2023-06
出版者
Karger
収録物名
Liver Cancer
巻(号)
12(2)
ページ
156-170
抄録
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial.Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib.Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (< 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without.Conclusion: Baseline low serum CXCL9 (< 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
2235-1795
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1159/000527759